1
|
Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM, Grinberg N, Puentes T, Furst MJL, Julio Méndez S, Lupo S, Suárez C, Agostini M, Cassetti I, Bologna R, Salud H, Cahn P, Patterson P, Krolewiecki A, David DO, Luna N, Cruceta A, Pich J, Varea S, Carné X, Mallolas J, Clotet B, Romeu J, Cruz L, Arrizabalaga J, Iribarren JA, Rodríguez F, Von Wichmann MA, Jimeno B, Pulido F, Rubio R, Flores J, González-Lahoz J, Rodríguez-Rosado R, Núñez M. Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy. Antivir Ther 2004. [DOI: 10.1177/135965350400900615] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. Methods Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly assigned to continue with this therapy or to change to a twice-daily indinavir/ritonavir (800/100 mg) regimen. The Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire was used as the HRQoL measure. Results A total of 118 patients participated in the study, of which 59 (50%) were randomly assigned to continue with the three-times-daily regimen. Patients had a mean age of 39 years and 80% of them were male. At baseline, subjects included in the three-times-daily group presented a significantly greater number of symptoms than subjects in the twice-daily group, but no statistically significant differences were observed in MOS-HIV scores between the groups. In the intention-to-treat (ITT) analysis, a reduction in HRQoL scores was observed in both groups, which was greater in the twice-daily group. In the per protocol analysis, reduction of HRQoL was minimal. Conclusions A HRQoL deterioration, greater in the twice-daily group, was observed in this study in the ITT analysis, while HRQoL remained stable in both groups in patients who continued with and tolerated the allocated regimen.
Collapse
Affiliation(s)
| | - Xavier Badía
- Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- HO Statistics & Modelling, Health Outcomes Research Group, Barcelona, Spain
| | | | - Irene Moral
- HO Statistics & Modelling, Health Outcomes Research Group, Barcelona, Spain
| | - Montse Roset
- HO Statistics & Modelling, Health Outcomes Research Group, Barcelona, Spain
| | | | | | | | - Beatriz Rosón
- Hospital Universitario de Bellvitge, Barcelona, Spain
| | | | - N Grinberg
- Hospital Alvarez, Buenos Aires, Argentina
| | | | | | | | - S Lupo
- Centro Caici, Rosario, Argentina
| | - C Suárez
- Centro Caici, Rosario, Argentina
| | | | | | | | | | - P Cahn
- Fundación Huésped, Buenos Aires, Argentina
| | | | | | - DO David
- Hospital Rawson, Córdoba, Argentina
| | - N Luna
- Hospital Rawson, Córdoba, Argentina
| | | | - J Pich
- Hospital Clinic, Barcelona, Spain
| | - S Varea
- Hospital Clinic, Barcelona, Spain
| | - X Carné
- Hospital Clinic, Barcelona, Spain
| | | | - B Clotet
- Hospital Germans Trias i Pujol, Badalona, Spain
| | - J Romeu
- Hospital Germans Trias i Pujol, Badalona, Spain
| | - L Cruz
- Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - JA Iribarren
- Hospital Ntra Sra de Aranzazu, San Sebastián, Spain
| | - F Rodríguez
- Hospital Ntra Sra de Aranzazu, San Sebastián, Spain
| | | | - B Jimeno
- Hospital Ntra Sra de Aranzazu, San Sebastián, Spain
| | - F Pulido
- Hospital 12 de Octubre, Madrid, Spain
| | - R Rubio
- Hospital 12 de Octubre, Madrid, Spain
| | - J Flores
- Hospital Arnau de Vilanova, Valencia, Spain
| | | | | | - M Núñez
- Hospital Carlos III, Madrid, Spain
| |
Collapse
|